Recent studies have uncovered a frightening association between the well-understandn diabetes and weight loss medications, Ozempic and Wegovy, with a unfrequent eye disorder that may cause blindness.
A study, unveiled in the medical journal JAMA Ophthalmology, alerted that individuals on those medications compriseing semaglutide have a much huger percentage chance of acquiring NAION, or, more accurately understandn by its acronym, non-arteritic anterior ischaemic selectic neuropathy.
This is described by a deficiency of flow thcimpolite the selectic nerve, suddenly damaging one’s vision since that nerve has more than one million strands. NAION is a unfrequent condition, shapeing only 2 to 10 people per 100,000. It is the second directing cause of selectic nerve blindness, and there is currently no effective remedy.
The study uncovered that those using semaglutide for diabetes were four times more foreseeed to lengthen NAION than those not using the drug. Those using it for weight loss had even wonderfuler danger-more than seven times higher.
“To be perfectly evident, I would not get my discoverings and use them to recommfinish that acunderstandledgeings stop taking their medications,” says Dr Rizzo. “Our discovering was reassociate the first possible beginant adverse discovering with these medications. It may fair merit extra alert in the consideration between doctors and acunderstandledgeings about who may use this medicine.”
According to the study, semaglutide is connected to a seven-fbetter incrmitigated danger of NAION when getn to treat obesity and a four-fbetter incrmitigated danger when used to treat type 2 diabetes.
Among the 710 acunderstandledgeings with Type 2 diabetes, semaglutide users had an 8.9% chance of lengthening NAION, while those on other medicines had a 1.8% chance.
The rate of NAION lengthenment was 6.7% for acunderstandledgeings deal withed semaglutide for weight loss and 0.8% for acunderstandledgeings on other medicines.
